Product Details
Product Name:
(-)-Epiafzelechin |
CAS No.:
24808-04-6 |
Purity:
98% |
Supply Ability:
10g |
Release date:
2024/11/06 |
Product Introduction
Bioactivity
名稱 | (-)-Epiafzelechin |
描述 | (-)-Epiafzelechin is a COX inhibitor with antioxidant and anti-inflammatory activity, osteoprotective effects in a mature ovariectomized mouse model, ability to stimulate osteoblast activity and inhibit osteoclast activity. |
體外活性 | (-)-Epiafzelechin exhibits significant antioxidant activity with an EC50 of 20.9μM[1]. |
存儲(chǔ)條件 | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 30 mg/mL (109.38 mM), Sonication is recommended.
|
關(guān)鍵字 | ()Epiafzelechin | Epiafzelechin |
相關(guān)產(chǎn)品 | Ibuprofen | Acetaminophen | Diclofenac sodium | Propyl gallate | Diclofenac Potassium | Neohesperidin | L-Cystine | Paradol | Indomethacin sodium hydrate | Revaprazan hydrochloride |
相關(guān)庫 | 經(jīng)典已知活性庫 | 中藥單體化合物庫 | 中藥抗炎分子庫 | 高通量篩選天然產(chǎn)物庫 | 抗衰老化合物庫 | 已知活性化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:848249-35-4
$47.00 / 1mg
-
CAS:1029872-54-5
$50.00 / 10mg
-
CAS:1057666-04-2
$74.00 / 1mg
Recommended supplier
Product name |
Price |
|
Suppliers |
Update time |
|
$0.00/5mg |
|
Shanghai Standard Technology Co., Ltd.
|
2020-05-25 |